Evidence map›Paper›PMID 42891015›Full record

ArticleOxford open immunology2026

An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial.

Mark A Faghy, Jade Chynoweth, Anton Barnett, Lindsay Skipper, Victoria Allgar, Helen Neilens, Kayle-Anne Sands, Amber Lord, Helen Hambly, Paigan J Aspinall and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxford open immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mark A FaghySchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, LE11 3TU, United Kingdom.ORCID https://orcid.org/0000-0002-8163-7032
Jade ChynowethMedical Statistics Research Group, University of Plymouth, Plymouth, PL4 8AA, United Kingdom.
Anton BarnettMedical Statistics Research Group, University of Plymouth, Plymouth, PL4 8AA, United Kingdom.
Lindsay SkipperCollege of Health and Humanities, University of Derby, Derby, DE22 1GB, United Kingdom.
Victoria AllgarMedical Statistics Research Group, University of Plymouth, Plymouth, PL4 8AA, United Kingdom.
Helen NeilensPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, PL6 8BU, United Kingdom.
Kayle-Anne SandsPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, PL6 8BU, United Kingdom.
Amber LordPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, PL6 8BU, United Kingdom.
Helen HamblyPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, PL6 8BU, United Kingdom.
Paigan J AspinallPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, PL6 8BU, United Kingdom.
Chris RollinsonPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, PL6 8BU, United Kingdom.
W David StrainFaculty of Health and Life Sciences, University of Exeter, Exeter, EX4 4QJ, United Kingdom.
Rebecca OwenCollege of Health and Humanities, University of Derby, Derby, DE22 1GB, United Kingdom.
Callum ThomasCollege of Health and Humanities, University of Derby, Derby, DE22 1GB, United Kingdom.
Marie J GriggCollege of Health and Humanities, University of Derby, Derby, DE22 1GB, United Kingdom.
Sascha H KranenFaculty of Health and Life Sciences, University of Exeter, Exeter, EX4 4QJ, United Kingdom.
Kinan MokbelFaculty of Health and Life Sciences, University of Exeter, Exeter, EX4 4QJ, United Kingdom.
Karen M KnappFaculty of Health and Life Sciences, University of Exeter, Exeter, EX4 4QJ, United Kingdom.
Hairil Abdul RazakFaculty of Health and Life Sciences, University of Exeter, Exeter, EX4 4QJ, United Kingdom.
Ruth AshtonResearch Centre for Healthcare and Communities Transformation, Coventry University, Coventry, CV1 5FB, United Kingdom.
Ian MaidmentCollege of Health and Life Sciences, Aston University, Birmingham, B4 7ET, United Kingdom.ORCID https://orcid.org/0000-0003-4152-9704
Tom BewickUniversity Hospitals of Derby and Burton NHS Foundation Trust, Derby, DE22 3NE, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the feasibility of a five‑day IV remdesivir intervention for individuals with LC. Seventy-three participants aged

Indexed as

Long COVIDPost-COVID syndromeRemdesivir

Identifiers

PMID42891015
PMCPMC13672820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.